Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000380305 | SCV000340530 | uncertain significance | not provided | 2016-03-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000698716 | SCV000827396 | uncertain significance | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2021-01-15 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SYNE1-related disease. ClinVar contains an entry for this variant (Variation ID: 286929). This sequence change replaces valine with alanine at codon 6778 of the SYNE1 protein (p.Val6778Ala). The valine residue is highly conserved and there is a small physicochemical difference between valine and alanine. |
Gene |
RCV000380305 | SCV001990673 | uncertain significance | not provided | 2019-03-26 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Athena Diagnostics | RCV000380305 | SCV005622605 | uncertain significance | not provided | 2024-04-26 | criteria provided, single submitter | clinical testing |